Urgineaglyceride A: a new monoacylglycerol from the Egyptian <i>Drimia maritima</i> bulbs

<div><p>One new compound, (2<i>S</i>)-1-<i>O</i>-(<i>Z</i>)-tetracos-6-enoate glycerol (<b>1</b>) named urgineaglyceride A, along with six known compounds, 3,5,7,3′,5′-pentahydroxydihydroflavonol (<b>2</b>), stigmasterol (<b>3</b>), (25<i>S</i>)-5β-furostane-3β-22α-26-triol (<b>4</b>), scillaridin A (<b>5</b>), (2<i>S</i>)-(+)-2-hydroxynaringenin-4′-<i>O</i>-β-d-glucopyranoside (<b>6</b>) and quercetin-3′-<i>O</i>-β-d-glucopyranoside (<b>7</b>), were isolated from the EtOAc fraction of <i>Drimia maritima</i> (L.) Stearn bulbs. Their structures were secured based on their IR, UV, 1D and 2D NMR data, in addition to HR-MS data and comparison with the literature data. The isolated compounds were evaluated for their <i>in vitro</i> growth inhibitory activity against A549 non-small cell lung cancer (NSCLC), U373 glioblastoma (GBM) and PC-3 prostate cancer cell lines. Compounds <b>2</b> and <b>3</b> displayed variable activities against the tested cancer cell lines. Compound <b>2</b> was a selective inhibitor of the NSCLC cell line with an IC₅₀ of 2.3 μM, whereas <b>3</b> was selective against GBM with IC₅₀ of 0.5 μM and against PC-3 with 2.0 μM.</p></div